Immunomedics, Inc. - Product Pipeline Review - 2015

Published: Dec, 2015 | Pages: 83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Immunomedics, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Immunomedics, Inc. - Product Pipeline Review - 2015', provides an overview of the Immunomedics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immunomedics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Immunomedics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Immunomedics, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Immunomedics, Inc.'s pipeline products

Reasons To Buy

- Evaluate Immunomedics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Immunomedics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Immunomedics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Immunomedics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immunomedics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Immunomedics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Immunomedics, Inc. Snapshot 7
Immunomedics, Inc. Overview 7
Key Information 7
Key Facts 7
Immunomedics, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Immunomedics, Inc. - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Immunomedics, Inc. - Pipeline Products Glance 16
Immunomedics, Inc. - Late Stage Pipeline Products 16
Phase III Products/Combination Treatment Modalities 16
Immunomedics, Inc. - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Immunomedics, Inc. - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Immunomedics, Inc. - Unknown Stage Pipeline Products 21
Unknown Products/Combination Treatment Modalities 21
Immunomedics, Inc. - Drug Profiles 22
clivatuzumab tetraxetan 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
epratuzumab 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
labetuzumab govitecan 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
sacituzumab 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
veltuzumab 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
IMMU-110 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
milatuzumab 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
TF-2 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
yttrium Y 90 epratuzumab tetraxetan 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
IMMU-114 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
14-3s 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
19-3s 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
1R-15-15 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
1R-E1-E1 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
20-3s 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
202-b 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
E1-3s 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Recombinant Protein to Agonize Interferon Lamda Receptor 1 for Oncology and Infectious Diseases 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
TF-12 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
15-3s 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
1R-3s 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
C2-3s 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
M1-3s 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Monocloncal Antibody to Target CD-19 for Oncology 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Immunomedics, Inc. - Pipeline Analysis 57
Immunomedics, Inc. - Pipeline Products by Target 57
Immunomedics, Inc. - Pipeline Products by Route of Administration 59
Immunomedics, Inc. - Pipeline Products by Molecule Type 60
Immunomedics, Inc. - Pipeline Products by Mechanism of Action 61
Immunomedics, Inc. - Recent Pipeline Updates 63
Immunomedics, Inc. - Dormant Projects 78
Immunomedics, Inc. - Discontinued Pipeline Products 79
Discontinued Pipeline Product Profiles 79
ImmuRAIT-LL2 79
veltuzumab 79
Immunomedics, Inc. - Company Statement 80
Immunomedics, Inc. - Locations And Subsidiaries 81
Head Office 81
Other Locations & Subsidiaries 81
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 82
Disclaimer 83

List of Tables

Immunomedics, Inc., Key Information 7
Immunomedics, Inc., Key Facts 7
Immunomedics, Inc. - Pipeline by Indication, 2015 9
Immunomedics, Inc. - Pipeline by Stage of Development, 2015 12
Immunomedics, Inc. - Monotherapy Products in Pipeline, 2015 13
Immunomedics, Inc. - Partnered Products in Pipeline, 2015 14
Immunomedics, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 15
Immunomedics, Inc. - Phase III, 2015 16
Immunomedics, Inc. - Phase II, 2015 17
Immunomedics, Inc. - Phase I, 2015 18
Immunomedics, Inc. - Preclinical, 2015 19
Immunomedics, Inc. - Discovery, 2015 20
Immunomedics, Inc. - Unknown, 2015 21
Immunomedics, Inc. - Pipeline by Target, 2015 57
Immunomedics, Inc. - Pipeline by Route of Administration, 2015 59
Immunomedics, Inc. - Pipeline by Molecule Type, 2015 60
Immunomedics, Inc. - Pipeline Products by Mechanism of Action, 2015 61
Immunomedics, Inc. - Recent Pipeline Updates, 2015 63
Immunomedics, Inc. - Dormant Developmental Projects,2015 78
Immunomedics, Inc. - Discontinued Pipeline Products, 2015 79
Immunomedics, Inc., Other Locations 81
Immunomedics, Inc., Subsidiaries 81